Exploring the best treatment options for BRAF-mutant metastatic colon cancer

The BRAF(V600E) mutation is a well-accepted poor prognostic factor in patients with metastatic colorectal cancer (mCRC), as it confers Ras-independent stimulation of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway involved in proliferation, migration, angiogenesis...

Descripción completa

Detalles Bibliográficos
Autores principales: Taieb, Julien, Lapeyre-Prost, Alexandra, Laurent Puig, Pierre, Zaanan, Aziz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738120/
https://www.ncbi.nlm.nih.gov/pubmed/31353365
http://dx.doi.org/10.1038/s41416-019-0526-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738120/
https://www.ncbi.nlm.nih.gov/pubmed/31353365
http://dx.doi.org/10.1038/s41416-019-0526-2

Ejemplares similares